Industry

Flow VIT® Test Kits: The Next Step in Specific Probiotic Enumeration

In July 2024, the journal Frontiers in Microbiology presented a groundbreaking method that overcomes this hurdle: the Flow-FISH method.

Probiotic intervention in the gut–prostate axis with novaPROX combo: insights from an in vitro study

The study published on Foods Journal researched the mechanisms of action of Probionova's novaPROX product using a 3D intestinal barrier model and a co-culture prostatic model.

The evolution of REBYOTA: milestones in microbiome-based therapeutics

On the second anniversary of its launch, Ferring Pharmaceuticals’ REBYOTA remains a landmark innovation in the prevention of recurrent Clostridioides difficile.

Innovative Potential of Lonza’s Capsugel® Enprotect® Capsules in Targeted Live Biotherapeutics and Pharmaceutical Applications

Lonza's capsules ensures targeted intestinal delivery enhancing stability and therapeutic efficacy for LBPs and pharmaceutical applications.

Unlocking the hidden world of the small intestine: a new frontier in microbiome science

Cmbio announces a strategic partnership with Nimble Science to deliver first in class high-quality, multi-omic data insights from the small intestine.

Cmbio® strengthens its digital biology platform with acquisition of Eagle Genomics’ assets

The acquisition will enhance its ability to address the needs of a growing market, empowering researchers and industries worldwide.

Revolutionizing treatment for Acute Graft-versus-Host Disease: MaaT Pharma’s groundbreaking Phase 3 results

The live biotherapeutics market is forecasted to exceed $4 billion by 2030, driven by advancements like MaaT013.

Gut to lung: how a new Akkermansia muciniphila strain is reshaping respiratory health

Its emergence in the respiratory health sector represents a paradigm shift, offering promising avenues for innovation and investment.

Microbio’s MS-20 shows breakthrough potential in enhancing Keytruda for advanced lung cancer

The study revealed that MS-20 dramatically improved treatment outcomes, tripling the objective response rate (ORR) to 75% when combined with Keytruda.

MaaT Pharma reports positive Phase 1b results for MaaT033 in ALS, setting the stage for future advances

A significant milestone for both microbiome research and neurodegenerative diseases.

Subscribe to MicrobiomePost newsletter

Take full advantage of MicrobiomePost‘s features.

Scroll to Top